Clinical Trials Browser

Phase 1 × Metastatic Solid Tumors × Ipilimumab × Clear all

NCT03388632 2025-12-18

Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

Phase 1 Completed

31 enrolled 20 charts

Other solid neoplasm

Metastatic Solid Tumors